MA50670A - Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose - Google Patents
Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible doseInfo
- Publication number
- MA50670A MA50670A MA050670A MA50670A MA50670A MA 50670 A MA50670 A MA 50670A MA 050670 A MA050670 A MA 050670A MA 50670 A MA50670 A MA 50670A MA 50670 A MA50670 A MA 50670A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody compositions
- new formulations
- dose antibody
- stabilize low
- stabilize
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D65/38—Packaging materials of special type or form
- B65D65/42—Applications of coated or impregnated materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565178P | 2017-09-29 | 2017-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50670A true MA50670A (fr) | 2020-08-05 |
Family
ID=65896542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050670A MA50670A (fr) | 2017-09-29 | 2018-09-28 | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190099489A1 (fr) |
| EP (1) | EP3688033A4 (fr) |
| JP (1) | JP2020535181A (fr) |
| MA (1) | MA50670A (fr) |
| WO (1) | WO2019064263A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| KR20220003562A (ko) * | 2019-04-23 | 2022-01-10 | 사노피 | 항-cd38 항체 및 제형 |
| CA3157652A1 (fr) * | 2019-10-16 | 2021-04-22 | Janssen Vaccines & Prevention B.V. | Produit de vaccin |
| BR112022007776A2 (pt) * | 2019-10-25 | 2022-07-05 | Amgen Inc | Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína |
| JP2023512446A (ja) * | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物 |
| WO2021222355A1 (fr) * | 2020-04-29 | 2021-11-04 | Amgen Inc. | Formulation pharmaceutique |
| AR123340A1 (es) * | 2020-08-26 | 2022-11-23 | Janssen Biotech Inc | FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET |
| EP4313894A1 (fr) * | 2021-03-25 | 2024-02-07 | SCHOTT Pharma AG & Co. KGaA | Récipient pharmaceutique |
| EP4696321A1 (fr) | 2023-04-14 | 2026-02-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé de stabilisation d'une préparation pharmaceutique contenant des protéines |
| CN119950461B (zh) * | 2025-02-10 | 2025-11-14 | 江苏长泰药业股份有限公司 | 一种吸入用异丙托溴铵溶液及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19921303C1 (de) * | 1999-05-07 | 2000-10-12 | Schott Glas | Glasbehälter für medizinische Zwecke |
| ATE389414T1 (de) * | 1999-09-08 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben |
| US8025915B2 (en) * | 2006-01-11 | 2011-09-27 | Schott Ag | Method of preparing a macromolecule deterrent surface on a pharmaceutical package |
| AU2007212147A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| CN106443002A (zh) * | 2007-10-22 | 2017-02-22 | 贝克顿·迪金森公司 | 评价在含有机基聚硅氧烷的悬浮液中蛋白质聚集的方法 |
| EP2640750A1 (fr) * | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents et méthodes de traitement de maladies qui sont corrélées à une expression de bcma |
| EP2857371A4 (fr) * | 2012-05-28 | 2015-12-16 | Namicos Corp | Récipient de verre, et procédé de fabrication de celui-ci |
| CN105209069B (zh) * | 2013-03-13 | 2019-08-23 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
| TW201501724A (zh) * | 2013-03-15 | 2015-01-16 | Glaxosmithkline Ip No 2 Ltd | 低濃度抗體調配物 |
| CN104057880B (zh) * | 2014-07-09 | 2016-04-06 | 郑运婷 | 车门防撞装置 |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
-
2018
- 2018-09-28 JP JP2020517815A patent/JP2020535181A/ja active Pending
- 2018-09-28 US US16/145,324 patent/US20190099489A1/en not_active Abandoned
- 2018-09-28 WO PCT/IB2018/057565 patent/WO2019064263A1/fr not_active Ceased
- 2018-09-28 MA MA050670A patent/MA50670A/fr unknown
- 2018-09-28 EP EP18861358.2A patent/EP3688033A4/fr active Pending
-
2021
- 2021-10-18 US US17/503,759 patent/US20220202937A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190099489A1 (en) | 2019-04-04 |
| EP3688033A4 (fr) | 2021-06-23 |
| US20220202937A1 (en) | 2022-06-30 |
| EP3688033A1 (fr) | 2020-08-05 |
| JP2020535181A (ja) | 2020-12-03 |
| WO2019064263A1 (fr) | 2019-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50670A (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
| CY1122718T1 (el) | Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων | |
| EP3548000A4 (fr) | Compositions pharmaceutiques d'atropine | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| EP3442973A4 (fr) | Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant | |
| EP3618871A4 (fr) | Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 | |
| EP3256149A4 (fr) | Formulations pour administration orale d'agents actifs | |
| MA56049A (fr) | Formulations stabilisées contenant des anticorps anti-angptl3 | |
| EP3419599A4 (fr) | Formulations d'antagonistes d'il-6 et leurs utilisations | |
| MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| EP3773721A4 (fr) | Formulations d'immunoconjugué anti-cd79b stables | |
| EP3412344A4 (fr) | Composition d'agent extincteur | |
| MA54052A (fr) | Formulation d'anticorps | |
| EP3820980A4 (fr) | Compositions d'esterquats | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| EP3927729A4 (fr) | Formulation d'anticorps thérapeutique | |
| MA54139A (fr) | Formulation d'anticorps | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| UA120999C2 (uk) | Естери оксаборолу та їх використання | |
| EP3463259A4 (fr) | Compositions d'écran solaire | |
| MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
| MA55362A (fr) | Formulations stabilisées contenant des anticorps anti-il-33 | |
| EP3452441A4 (fr) | Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées | |
| MA45158A (fr) | Composition pharmaceutique comprenant de l'éteplirsen | |
| MA45451A (fr) | Formulations tensioactives destinées à l'inhalation |